AI in Women's Health - global virtual conference
Join us for a global virtual conference bringing together the people asking bigger questions, challenging long-standing gaps in care, and putting AI to work for women’s health.
Hear from leaders, researchers, clinicians and innovators as they explore what it takes to build technology that understands women’s lives and makes a meaningful difference in care.
We’ll explore how AI could help connect insights across the full women’s health journey, from earlier detection to more tailored support, and see emerging applications in action.
We’ll examine the gaps in data that have left women’s health overlooked and ask what it takes to build AI that reflects women’s experiences, symptoms and needs.
We’ll also consider what this progress could mean for women seeking care: being heard sooner, receiving clearer answers and having a greater say in decisions about their health.
We’ll look at how AI could connect insights across the full women’s health journey, helping clinicians recognise patterns earlier, make more informed decisions and offer support tailored to each person.
You’ll see emerging applications in action at our Innovation Showcase. Throughout, we’ll consider how AI can make care more personal and responsive while preserving the trust, empathy and human connection at the heart of good healthcare.
AGENDA
Welcome words by the organising team - 2pm - 2:10pm GMT
Connecting the Dots: AI Across the Women’s Health Journey - panel discussion - 2:10pm - 2:55pm GMT
How can AI help connect the dots across women’s health? This panel explores its evolving role in understanding individual health needs, supporting informed decisions and connecting care across the patient journey. Bringing together perspectives from fertility and precision women’s health, the discussion will consider the opportunities and challenges of AI across women’s health.
Our speakers:
Joanna Balogh-Reynolds, Senior Vice President, Channel Partnerships at Progyny
Joanna Balogh-Reynolds is Senior Vice President, Channel Partnerships at Progyny, where she leads the company’s product partner ecosystem and advances strategic relationships that strengthen Progyny’s comprehensive women’s health offering. With more than 15 years of experience in healthcare innovation, she brings together her clinical background as a Doctor of Nursing Practice and deep expertise in building sustainable, scalable care models that support women at every life stage. An adjunct professor and recognised thought leader in healthcare informatics, Joanna is passionate about creating evidence-based solutions for historically underserved women’s health needs, including menopause.
Progyny is a global leader in women’s health and family-building solutions, trusted by leading employers, health plans, and benefit purchasers. We envision a world where everyone can achieve their dreams of family and optimal health. Our outcomes demonstrate that comprehensive, inclusive, and intentionally designed solutions benefit employers, patients, and physicians alike.
Priyanka Jain, co-founder and CEO of Evvy
Priyanka Jain is the co-founder and CEO of Evvy, the leading vaginal microbiome platform, on a mission to close the gender health gap. Under her leadership, Evvy has built the world's largest vaginal microbiome dataset, launched EvvyAI — the first AI advisor for vaginal health — and serves over 100,000 patients and 3,000 practitioners. Evvy recently raised a $40M Series B. Previously, Priyanka was Head of Product at Pymetrics, where she led a 70+ person product, data science, and engineering team building AI for fairer hiring.
Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy’s groundbreaking Vaginal Health Test is the world’s only CLIA-certified, CLEP-approved mNGS test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways, Evvy provides 100,000+ patients with data-driven, personalised care for vaginal infections, fertility, menopause, and more. Evvy is backed by 15+ peer-reviewed publications & abstracts, including validation of their novel test methodology and a study demonstrating significant improvements to patient outcomes. Evvy has built the world’s largest dataset on the vaginal microbiome and is pioneering research to improve outcomes across the female lifespan.
Christy Prada, CEO at Future Fertility
Christy Prada is the CEO at Future Fertility, a Toronto-based AI company focused on closing critical information gaps in the fertility journey. She has a track record as a builder, spending her career creating and guiding high-performing teams across a range of fields, including developing and scaling new models for commercial growth at start-ups. Christy is also an investor as a Limited Partner with the Women’s Equity Lab, Toronto Chapter, investing in early-stage women-led ventures. Drawing on this experience, combined with her passion for finding innovative solutions to the world’s toughest healthcare challenges, Christy leads the Future Fertility team in its mission to empower fertility doctors, specialists, and patients with advanced AI-driven insights globally.
Future Fertility is a Canadian health technology company helping close important information gaps along the fertility journey — starting with the egg. For decades, egg quality has lacked a standardised approach to assessment and has largely been estimated based on age alone. Future Fertility is changing that by providing objective, personalised insights into egg quality through non-invasive, AI-powered analysis of egg images captured in fertility labs. Its tools are used in egg freezing, IVF, and donor egg programs to give patients and their care teams more information about the reproductive potential of individual eggs, helping support more informed conversations and decisions around fertility planning and treatment. Today, Future Fertility’s technology is used by more than 300 clinics across 35+ countries.
Donna Parr, Managing Partner of Cross-Border Impact Ventures
Donna Parr is a Managing Partner of Cross-Border Impact Ventures. She has over 30 years’ experience in venture and private equity investing and prior experience in corporate finance. She has worked as a portfolio manager in several venture and biotech funds and the private equity groups of two Canadian pension funds, including the Ontario Municipal Employees Retirement System (OMERS), where she ultimately headed the private equity and venture group for four years. Donna has operational experience as an Executive Director of CellAegis Devices, which developed a patented cardiovascular medical device, and as Manager of Business Development for a cleantech company. Current director roles include publicly traded Constellation Software and Topicus.com, as well as a number of CBIV investee companies. She holds an MBA from the Schulich School of Business and Master’s degrees from the University of Toronto
Cross-Border Impact Ventures (CBIV) is an impact venture capital firm on a mission to revolutionise venture investing in health technology. CBIV specialises in investing in early-growth-stage health technology companies commercialising medical devices, diagnostic tools, therapeutics and digital health solutions incorporating sophisticated technologies like Artificial Intelligence (AI) and Machine Learning (ML), focused on addressing healthcare conditions that impact women and children specifically, differently, or disproportionately. All innovations they finance are relevant to women’s, children’s, and adolescents’ health and located in North America and Europe, with the ability to scale technologies to emerging markets. The firm is driven by the belief that good health should not be restricted by gender, age, race, wealth, or borders and seeks to expand access to its portfolio’s world-class technologies inclusively and globally.
Moderated by Agata Bendik, co-founder of Holos
Agata Bendik is an award-winning founder and ex-operator working at the intersection of technology, investment and women's health. She was part of the founding team of Plug and Play UK, where she helped build its healthtech work, and launched London's scientific and innovation network, Venture Café, in partnership with Advanced Research + Invention Agency (ARIA). After more than a decade in the UK tech and innovation ecosystem, she returned to Poland and is now building Holos, a platform developing a more coordinated care pathway for women with hormonal and metabolic conditions.
Holos is a Polish women's health company on a mission to shorten the road to diagnosis for hormonal and metabolic conditions — a journey that today often takes women over two years — towards a single, well-prepared visit. Starting with PMOS and insulin resistance, Holos offers personalised care that combines a structured intake, individually selected diagnostics and support from clinicians, so women no longer have to piece together tests and specialist visits on their own. Holos builds a longitudinal dataset that helps improve how these conditions are understood, diagnosed and managed. Founded by Agata Bendik (ex-Plug and Play) and Magda Zielińska (ex-ElevenLabs), Holos is starting in Poland, with ambitions to expand across Europe.
Why Women's Health Needs Its Own AI Infrastructure, panel discussion - 2:55pm - 3:40pm GMT
What would AI infrastructure designed around women’s health look like, and why is it needed? This panel brings together perspectives from across the sector to explore the data, research and collaboration needed to build AI that reflects women’s health needs, alongside the challenges of creating a shared foundation for innovation.
Our speakers:
Audrey Tsang, Board Member and former CEO of Clue
Audrey Tsang is an operator, advisor, and coach at the intersection of consumer technology and digital health. Most recently, she served as CEO of Clue, the number one women-led period and cycle tracker, trusted and loved by millions globally. She leads the company through transformational growth as a consumer subscription and regulated SaMD business. Before that, she built a 15-year career in consumer tech leading products at Clue, Pinterest, HotelTonight, and Yelp. She currently advises and coaches founders and startups building products that matter.
More than 10 million people in 190 countries use Clue to understand their periods and their health. Built in Berlin on the belief that female health deserves real science and strict privacy, Clue turns more than 750 million opted-in cycles into insights for every life stage, and works with researchers at MIT, Oxford and Columbia to close the gap in what we know and can do about menstrual and reproductive health.
Dr Kathleen Jordan, Chief Medical Officer at Midi Health
Dr Kathleen Jordan is the Chief Medical Officer at Midi Health, a leading menopause care platform serving women in all 50 states. As a proponent of digital health and solving access issues, Dr Jordan has worked to leverage innovative technology into patient care and joined the founding team at Midi to design and lead a care platform to serve women in perimenopause and menopause. She previously ran her own practice and was Chief Medical Officer at Saint Francis Memorial Hospital in San Francisco, setting up new service lines and embracing telehealth as an access platform. As a menopause-certified provider and trained internist, Dr Jordan now leads a team of hundreds of Midi clinicians serving women in all 50 states via virtual telehealth, supporting hormone needs, health screens, weight management and optimising bone, brain and cardiovascular health. Her expertise has been seen in The New York Times, The Washington Post, CNN International, Yahoo News, People Magazine, Time, and many others. She is a graduate of the UCLA School of Medicine and Stanford University. Since its inception in 2021, Midi Health has demonstrated exceptional growth and garnered substantial recognition. Midi Health achieved "unicorn" status following the successful completion of its Series D funding round and has been prominently featured on lists such as Forbes top startups in 2024 and TIME100 Most Influential Companies of 2025.
Midi Health is a specialised virtual care platform dedicated to modernising women's healthcare. The nation's fastest-growing women's telehealth company, Midi combines medical expertise, purpose-built AI, and compassionate care to deliver personalised treatment plans for every stage of a woman's health journey. Covered by most major insurance plans in all 50 states, Midi is building on its leadership in perimenopause and menopause care to fill the critical health gaps women face at every age.
Morgan Rose, Chief Science Officer at EmaEQ
Morgan Rose is the Chief Science Officer at Ema, where she leads applied clinical AI strategy with expertise in women's health. A Certified Nurse-Midwife (CNM), Women's Health Nurse Practitioner (WHNP), and International Board Certified Lactation Consultant (IBCLC), Morgan brings over a decade of experience supporting women through every stage of life. She lives in Manhattan and is a proud single mother to a spunky eight-year-old and two puppies.
Ema EQ is an AI company building a new standard of intelligence for women’s health. Women have long navigated a healthcare system built on incomplete data and gaps in understanding, and general-purpose AI risks carrying those same gaps into the future. EmaEQ exists to change that, building AI around the context, complexity and realities of women’s health so women can claim greater agency over their health in a future shaped by AI. Its flagship product, Ema, is a proprietary AI system built specifically for women’s health. Ema combines deep health knowledge with contextual and emotional intelligence to deliver personalised guidance, help people navigate their health journeys, and take meaningful action. Designed to integrate seamlessly into existing products and services, Ema enables diagnostic, pharmaceutical, and health technology partners to create more connected, intuitive experiences for their customers.
Moderated by Rachel Braun Scherl - healthcare entrepreneur, growth strategist, and women's health expert
Rachel Braun Scherl is a healthcare entrepreneur, growth strategist, and women's health expert who has spent more than 25 years building businesses, brands, and products across healthcare, with a specific focus on women's health. Today, she is focused on creating the connective tissue across the women's health ecosystem — founders and funders, providers and payors, companies and collaborators. As Managing Partner of SPARK Solutions for Growth, Rachel advises Fortune 500 companies and dozens of venture-backed startups on marketing strategy, business growth, innovation, partnerships, and go-to-market strategy. She is also co-founder and Head of Growth at 51&, a member-driven organisation advancing women's health through community, advocacy, research, and innovation. Rachel is a three-time founder and a marketing strategist/growth specialist, having worked with dozens of companies across the women’s health spectrum. She has raised millions of dollars in venture funding for her own ventures and others, and launched dozens of category-leading products into the marketplace. Rachel is a sought-after speaker at leading companies, corporations, conferences, and universities, with her perspectives being included in Forbes, Fortune, Inc., Huffington Post, CBS News, ABC News, and her research being published in Academy of Management Perspectives.
Can AI Finally Close the Diagnostic Gap in Women's Health? - panel discussion - 3:40pm - 4:25pm GMT
Could AI help address the delays and missed diagnoses women experience? This panel explores its potential to recognise overlooked symptoms, support earlier detection and improve diagnostic decisions, while considering the data gaps, bias and clinical challenges that could shape its impact.
Our speakers:
Shilpi Gupta, founder and CEO of Qyn Labs
Shilpi Gupta is the founder and CEO of Qyn Labs, which is developing technology for frequent hormone measurement from blood samples. Her career spans consumer robotics at iRobot, large-scale systems at Amazon Robotics and a head of product role at Pison. At Pison, she worked on electromyography and brain-computer interfaces, including applications for monitoring neuromuscular disease.
Qyn Labs is building a new way to understand hormones through blood-based measurement, meaningful patterns, and better context over time—helping people see what’s changing in their bodies and make more informed decisions about their health. By combining on-demand blood testing with intelligent data interpretation, the company helps individuals establish their personal baseline — not guess against averages.
Shubhi Rao, founder and CEO of Uplevyl
Shubhi Rao is the founder and CEO of Uplevyl, an AI company building secure, women-centred intelligence hubs that transform authoritative data into actionable insights, collaboration tools, and learning programs. A STEM-trained entrepreneur and AI practitioner, she works at the intersection of gender and technology, with deep expertise in artificial intelligence, MLOps, retrieval-augmented generation, knowledge graphs, model governance, and data privacy.
Uplevyl is the first female-forward tech ecosystem — an AI-powered, multi-tenant platform built to partner with corporates and women’s organisations. While organisations bring their communities, Uplevyl provides the infrastructure: generative AI trained on women's datasets, personalised experiences, gender-literate AI agents for both members and administrators, data-driven insights, intelligent content systems, and private engagement hubs. Whether it’s acquiring new skills, building networks, or navigating career, health, and wealth choices, Uplevyl meets women where they are — and helps move them forward. If AI is becoming the next great brain, Uplevyl is building one that finally sees and serves women — not as an afterthought, but as the starting point.
Elena Rueda, CEO and co-founder of Dama Health
Elena Rueda is the CEO and co-founder of Dama Health, the specialist clinical AI company for women’s hormone health. A medical scientist turned venture builder, Elena studied medical science and genetics before earning a Master’s in Innovation, Entrepreneurship, and Management at Imperial College London, where she brought the two disciplines together. She went on to work in social care and to bring early-stage women’s health technology to market at Merck’s Innovation Center. Her early research into the epigenetics of drug response inspired her to look into drug response in women, since so little is known in this field. This led to her founding Dama to change that and better understand why and how women respond differently to the hormone therapies that are prescribed to them in many different stages of life, from contraception to HRT for menopause.
Dama Health is building the specialist clinical AI for women’s hormone health. The company researches how women respond to hormone therapies and translates those insights and datasets into clinical decision support that personalises care. The Dama Platform and AI copilot help clinicians across 250+ US clinics make prescribing decisions in menopause and perimenopause, contraception, PMOS, endometriosis, and metabolic health.
Esther Reynal de Saint-Michel, Founding Managing Partner of THENA Capital
Esther Reynal de Saint-Michel is the Founding Managing Partner of THENA Capital, a UK based MedTech venture capital fund focused on digital healthcare solutions and medical devices, with over 10 years of experience in growth strategy consulting and venture capital. For over 10 years before moving into VC investing, she has been a trusted advisor to large brands across consumer sectors and in particular within healthcare, advising them on consumer growth strategies and how best to adapt their commercial models to changing environments and trends. She is passionate about helping companies strengthen and adapt their business models to not only to achieve growth but also deliver against their vision. When this vision is about transforming patients’ experiences, giving access to capital and mentoring are even more impactful.
THENA Capital is a UK-based venture capital fund dedicated to accelerating the development of life-changing medical technology companies. We back high-growth businesses that are redefining health experiences through breakthrough digital solutions and fast-tracked devices.
Fund I focuses on UK-based early-stage innovations addressing critical unmet needs across chronic conditions, women’s health, oncology, cardiovascular care, care delivery, and more.
With deep sector expertise, THENA Capital is reshaping early-stage medtech investing—bringing strategic insight, clinical understanding, and a mission-driven approach to building the next generation of transformative health companies.
Moderated by Dr Bianca Schor, AI researcher in women's health
Dr Bianca Schor is an AI researcher in women's health. Bianca waited seven years before being diagnosed with endometriosis and adenomyosis. As a disabled woman, she decided to dedicate her academic career to improving the diagnosis of these conditions and women's healthcare more broadly. Bianca holds a PhD in Computer Science from the University of Cambridge, UK, where she focused on designing responsible AI systems for non-experts, including families, teenagers, and clinicians. Using the latest Deep-learning models, Bianca co-designed AI prototypes for ovarian cancer, endometriosis and uterine disorders, and joined Amsterdam UMC, The Netherlands, as an AI researcher specialising in gynaecological imagery. She now co-leads the Womain lab. In 2023, Bianca also founded the UK’s national AI for women’s health academic group, hosted at The Alan Turing Institute in London. In 2025, the group was recognised as an "AI visionary" for their work in this field by the National Health Service (NHS) and the Department of Health and Social Care (DHSC) in the UK. Since 2025, Bianca has also coordinated the Dutch national hospital consortium and the European WomAIn consortium on AI for endometriosis and uterine disorders, leading to multiple national and international research grants.
Innovation Showcase - presentations from 4:25pm - 5:50pm GMT
This showcase puts emerging ideas in the spotlight, bringing together companies using AI to address challenges in women’s health and share what comes next.
Our speakers:
Dr Federica Inturrisi, HPV and Cervical Cancer Prevention Specialist, La Fondation MSF
Dr Federica Inturrisi is an epidemiologist and molecular biologist specialised in cervical cancer prevention in low-resource settings. With a PhD focused on risk-based screening strategies, she previously led key components of the US National Cancer Institute's global PAVE consortium, where she contributed to AI-driven visual evaluation tools and chaired work on HPV self-sampling across Sub-Saharan Africa. In 2025, following extensive field experience in Tanzania and Malawi, she joined the MSF Foundation to advance HPV screening in LMICs. Dr Inturrisi is also an Affiliate Board Member of the International Papillomavirus Society.
The MSF Foundation (Fondation Médecins Sans Frontières) is an operational research and innovation lab dedicated to developing specialised digital and medical technologies for vulnerable populations in low-resource and crisis settings. Through open-source, human-centred innovations—including AI-driven diagnostic and clinical tools—the Foundation works to bridge the healthcare gap in underserved regions globally.
Quanda Francis, founder and CEO of Womb WatchAI®
Quanda Francis, MBA, is the founder and CEO of Womb WatchAI® and the author of AI Healthcare War Room, an Amazon #1 New Release. She pioneered Bio-Intent Orchestration Systems, a new category of artificial intelligence. Her mission of "Performance Equity" bridges health equity and technology fluency, reflected in her founding of the AI Technology Exposure Academy and the Court Culture Basketball Leadership Academy at NYU, which taught student-athletes how AI is applied in health and sports. She transformed the trauma of healthcare dismissal into a company building the operating system for women's health.
Womb WatchAI is building the AI operating system for women's health and a unified health mapping data infrastructure to better understand disease origination and disease pathology in women.
Sivan Sadan, co-founder and CEO of PinkStar Technologies
Sivan Sadan is a women’s health entrepreneur, investor and business executive with more than 25 years of experience across investment banking, venture capital, and company leadership. She is co-founder and CEO of PinkStar Technologies, a women-led company originating at Sheba Medical Center that is developing AI-based decision support software for breast MRI. Before founding PinkStar, Sivan served as CFO and Executive Vice President of HeraMED (ASX:HMD), a digital health company focused on connected maternity care. Her work in women’s health has been recognised by Women of Wearables, which named her one of its 200 Trailblazing Leaders in Women’s Health and FemTech in 2023. She is passionate about translating promising science and technology into real businesses, and bringing more capital, talent and attention to women’s health.
PinkStar is an AI technology company originating at Sheba Medical Center, developing AI-based decision support software for breast MRI. The technology is designed to support radiologists in classifying breast MRI findings, with the goal of earlier detection and more informed clinical decision-making. PinkStar is building its technology on diverse real-world clinical data and has entered into a collaboration agreement with Mount Sinai in New York to expand its US clinical data resources.
Yasmin Baba, co-founder and CTO of Amilis
Yasmin Baba is co-founder and CTO of Amilis. An electrical engineer with a master’s in Machine Learning from Imperial College London, she leads product and technology for Amya, a clinical system for doctors who see women, built to turn everyday women’s health care into structured data that closes long-standing evidence gaps.
Amilis is a UK-based women’s health data company. Its software, Amya, is a clinical system for private gynaecologists and fertility clinics that runs the whole practice, from appointments and records to payments, while structuring patient data to make sense of the complexity of women’s health.
Mette Andersen, founder of yume health
Mette Andersen is the founder of yume health. She brings her lived experience and two decades in product design, behavioural science and leading multidisciplinary teams to her mission: to transform how women access, navigate and manage hormonal health. A former teacher and certified coach, Mette shapes yume’s conversational core, bringing adult learning principles and the science of habit formation into every interaction.
Yume health is the lifelong, emotionally intelligent AI companion for every chapter of a woman’s hormonal health journey. Winglady, coach and science geek in one, yume blends natural conversation with the latest research to help women build body literacy, track what matters and take preventative action. Rather than focusing on a single condition or life stage, yume wires together what the health system can’t, joining the dots across months and years while democratising access to hyper-personal, evidence-based support.
Our sponsors and partners:
Progyny is a global leader in women’s health and family-building solutions, trusted by leading employers, health plans, and benefit purchasers. We envision a world where everyone can achieve their dreams of family and optimal health. Our outcomes demonstrate that comprehensive, inclusive, and intentionally designed solutions benefit employers, patients, and physicians alike.
Qyn Labs is building a new way to understand hormones through blood-based measurement, meaningful patterns, and better context over time—helping people see what’s changing in their bodies and make more informed decisions about their health. By combining on-demand blood testing with intelligent data interpretation, the company helps individuals establish their personal baseline — not guess against averages.
PinkStar is an AI technology company originating at Sheba Medical Center, developing AI-based decision support software for breast MRI. The technology is designed to support radiologists in classifying breast MRI findings, with the goal of earlier detection and more informed clinical decision-making. PinkStar is building its technology on diverse real-world clinical data and has entered into a collaboration agreement with Mount Sinai in New York to expand its US clinical data resources.
Be part of the conversation—join us on 18 November for the AI in Women’s Health virtual conference.